Brain scan study for multiple sclerosis treatment switch
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 70 years old
- You have been diagnosed with relapsing forms of MS (RMS)
- You have been taking ocrelizumab (Ocrevus) for at least 18 months and your last dose was 5 to 9 months ago
- You are stable and have not had an MS relapse in the past 30 days
- You do not have any metal implants or devices that make MRI or PET scans unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called remibrutinib in people with multiple sclerosis (MS). It uses MRI scans to see how well the drug works at reducing MS activity. This could help people with relapsing or progressive MS.
This study looks at whether MS relapses happen without any signs of new disease activity on an MRI scan. By tracking your symptoms and scans, researchers hope to better understand how MS affects people in real life. If you qualify, you may help improve future treatment decisions.
This study uses brain scans to look for hidden inflammation in people with multiple sclerosis who have not yet started a strong treatment. It aims to understand how this inflammation affects the disease and to help guide future therapies.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.